Lupin announced the launch of Posaconazole Delayed-Release Tablets, 100 mg, after its alliance partner AET Pharma
US Inc. (part of Tiefenbacher Group) received an approval for its ANDA from the United States Food
and Drug Administration.
Posaconazole Delayed-Release Tablets, 100 mg, are the generic equivalent of Noxafil DelayedRelease Tablets, 100 mg, of Merck Sharp & Dohme Corp, and are indicated for prophylaxis of invasive
Aspergillus and Candida infections in patients who are at high risk of developing these infections due
to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT)
recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with
prolonged neutropenia from chemotherapy.
Posaconazole Delayed-Release Tablets, 100 mg (RLD: Noxafil) had estimated annual sales of
USD 186 million in the U.
S. (IQVIA MAT December 2020).
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.